track b rapporteur report
DESCRIPTION
TRACK B RAPPORTEUR REPORT. JOSE R ARRIBAS on behalf of …. WHEN TO START. HPTN-052. STARTING > 350 vs 500 better than < 350 ?. Grinsztejn . THLBB05. WHAT TO START. SPRING-2. Raffi . THLBB04. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/1.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
TRACK B RAPPORTEUR REPORT
JOSE R ARRIBAS on behalf of…
![Page 2: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/2.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
![Page 3: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/3.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
![Page 4: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/4.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
![Page 5: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/5.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
WHEN TO START
![Page 6: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/6.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
HPTN-052
STARTING > 350 vs <250 (229). AIDS + Non-AIDS: No differenceAIDS: better (TB) >500 better than < 350 ?
Grinsztejn. THLBB05
![Page 7: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/7.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
WHAT TO START
![Page 8: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/8.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.orgRaffi. THLBB04
SPRING-2
![Page 9: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/9.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.orgRaffi. THLBB04
No difference by NUCs or high viral loadsNo INI mutations nor NRTI mutations were detected through 48 weeks on DTGNo withdrawals due to renal events Small increase in creatinine due to blockade of Cr secretion in DTG arm
DOLUTEGRAVIR QD NEW OPTION
NO RESISTANCE “UNPRECEDENTED”
![Page 10: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/10.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
DOLUTEGRAVIR POSSIBLE FOR
TEEN/KIDS(RALTEGRAVIR ALSO)
“CHEWING” RAL
Hazra. TUAB0203
![Page 11: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/11.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.orgGallant. TUAB0103
![Page 12: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/12.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Gallant. TUAB0103
No development of PI resistance in either group. Similar lipidsExpected small increase in serum creatinine (≈0.1 mg/dL) Iin the COBI armLow and comparable discontinuation rates due to renal AE Similar discontinuation rates due to bilirubin-related AEs
COBI AND RITONAVIR
CAN YOU SPOT THE DIFFERENCES?
![Page 13: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/13.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
HOW TO SWITCH
![Page 14: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/14.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.orgPalella. TUAB0104
Lower rate of virologic non-suppression in FTC/RPV/TDF (17/17 with transmitted K103N suppressed)Switching: improvement in fasting lipids and 10-year Framingham Risk Score
FTC/RPV/TDFStrong/simple switch option
![Page 15: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/15.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
In these three ARV trials < 15%
females. We need to do better!
![Page 16: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/16.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
RESISTANCE
![Page 17: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/17.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
0% 5% 10% 15% 20% 25% 30% 35% 40%0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
Eastern AfricaSouthern AfricaWestern and Central AfricaSouth-East Asia RegionWestern Pacific Regionother
Antiretroviral therapy coverage: % of people living with HIV receiving ART
Prev
alen
ce o
f NN
RTI r
esis
tanc
e m
u-ta
tions
: % o
f gen
otyp
es
Transmitted HIVDR (WHO surveys) Relationship between transmitted resistance to NNRTI and
ART coverage
MORE COVERAGE,
MORE OPTIONS, more (different)
resistanceBertagnolio. TUAB0305
![Page 18: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/18.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
TB
![Page 19: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/19.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
EFAVIRENZ C min % < 400 copies/mL
Luetkemeyer. TUAB0104
Do not support weight-based increase of EFV
during rifampin treatment
![Page 20: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/20.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
RAL new option for ART during TB treatment.
Optimal RAL dose yet to be defined
N. De Castro. THLBB01
![Page 21: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/21.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
HCV
![Page 22: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/22.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Lo Re. WEAB0102
Despite ART, HIV/HCV pts had higher risk of
hepatic decompensation than HCV-monoinfected pts
![Page 23: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/23.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
AGING/COMORBIDITIES
![Page 24: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/24.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Schouten. THAB0205
Comorbidities more prevalent amongst
HIV-positives compared to uninfected controls
of similar age
![Page 25: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/25.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Schouten. THAB0205
Death rates in people with access to care
AIDS still leading cause of death
Non AIDS cancers leading non-AIDS cause
of death
![Page 26: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/26.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
ADJUSTING TO TIME
![Page 27: TRACK B RAPPORTEUR REPORT](https://reader036.vdocument.in/reader036/viewer/2022062315/56815f61550346895dce4b86/html5/thumbnails/27.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
ADJUSTING TO SPACE